Preclinical Pharmacokinetics, Pharmacology and Toxicology of Lisdexamfetamine: A Novel d-Amphetamine Pro-Drug.

Related Articles

Preclinical Pharmacokinetics, Pharmacology and Toxicology of Lisdexamfetamine: A Novel d-Amphetamine Pro-Drug.

Neuropharmacology. 2014 Mar 1;

Authors: Hutson PH, Pennick M, Secker R

Abstract
Lisdexamfetamine dimesylate (LDX) is a novel prodrug of d-amphetamine that is currently used for the treatment of attention-deficit/hyperactivity disorder in children aged ≥6 years and adults. LDX is enzymatically cleaved to form d-amphetamine following contact with red blood cells which reduces the rate of appearance and magnitude of d-amphetamine concentration in the blood and hence the brain when compared with immediate-release d-amphetamine at equi-molar doses. Thus, the increase of striatal dopamine efflux and subsequent increase of locomotor activity following d-amphetamine is less prominent and slower to attain maximal effect following an equimolar dose of LDX. Furthermore, unlike d-amphetamine, the pharmacodynamic effects of LDX are independent of the route of administration underlining the requirement to be hydrolysed by contact with red blood cells. It is conceivable that these pharmacokinetic and pharmacodynamic differences may impact the psychostimulant properties of LDX in the clinic. This article reviews the preclinical pharmacokinetics, pharmacology, and toxicology of LDX.

PMID: 24594478 [PubMed – as supplied by publisher]

via http://ift.tt/1oy0EOy